The research team used a sophisticated sampling strategy that enabled the true performance of the polygenic risk score to be determined and not be influenced by the effects of age and sex.

MENLO PARK, Calif., Sept. 3, 2025 /PRNewswire/ -- MyOme, a leading clinical whole genome testing and polygenic risk modelling (PRS) company, today announced the launch of its Type 2 Diabetes (T2D) ...